KCT0007762招募中未知
Establishment of Non-Alcoholic Fatty Liver Disease Cohort for prevention and management of Cardio-cerebrovascular Disease
Seoul Metropolitan Government Seoul National University Boramae Medical Center0 个研究点目标入组 400 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Patients 19 years old and older
- •2) Patients with NAFLD
- •: patients who are suspected of having fatty liver with intrahepatic fat deposition on an imaging test or liver biopsy performed within 3 months.
- •3) Patients who consented to participate the study and signed a written informed consent
排除标准
- •1) Patients with significant alcohol intake of the following within 2 years prior to baseline (140 g or more per week for female, 210 g or more per week for male; types of drinks equivalent to 10 g of alcohol: 360 mL of beer, 120 mL of wine, 45 mL of whiskey)
- •2) Type 1 diabetes (insulin-dependent diabetes mellitus)
- •3) Patients with hepatobiliary disease that may show abnormal liver function without NAFLD (e.g., viral hepatitis such as HBV or HCV, drug-induced liver injury, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, hemochromatosis, etc.)
- •4) Patients with malignant tumors including liver cancer. But among them, patients with no recurrence within 5 years after the last treatment can be included.
- •5) Patients who have taken drugs that could cause fatty liver disease within 8 weeks from the baseline. (e.g., amiodarone, tamoxifen, methotrexate, tetracyclines, glucocorticoids (prednisone 10 mg or more per day), anabolic steroids, estrogen over the usual dose of hormone replacement therapy, valproate, etc.)
- •6) Patients who the investigators consider not suitable to participate in this study for the following reasons: severe renal impairment, severe lung disease, severe cardiovascular disease, severe neurological or psychiatric disease, muscular disease, etc.
- •7) Patients with a history of immune diseases such as inflammatory bowel disease, autoimmune thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, severe psoriasis, rheumatoid arthritis, etc.
- •8) Patients who are positive for anti-HIV antibody
- •9) Patients who are not suitable to be included in the study by the judgment of the investigators
研究者
相似试验
尚未招募
不适用
on alcoloholic liver disease in people living with HIVCTRI/2020/01/022630Maulana Azad Medical College
尚未招募
2 期
To study the effect of Safuf-e-Zaranbad in patients with Non-Alcoholic Fatty Liver DiseaseCTRI/2023/03/050355Central Council for Research in Unani Medicine New Delhi
尚未招募
不适用
on-alcoholic Fatty Liver Disease Dietary TrialACTRN12612000841875Catherine Properzi66
尚未招募
不适用
Research of Non-alcoholic fatty liver disease(NAFLD) and Non-alcoholic steatohepatitis(NASH) using the measuring instrument of ethanol metabolismJPRN-UMIN000024594Department of hepatology and pancreatology, Aichi Medical University90
尚未招募
Unknown
To check the the risk of liver damage due to Diabetes in young patients of Diabetes both type 1 and type 2.CTRI/2023/11/060051Dr. Sanjeev Gulati